智通财经网·2026-01-21 01:28Core Viewpoint - Zhaoyan New Drug (06127) is expected to experience a decline in revenue for 2025, while net profit is projected to increase significantly, driven by changes in the fair value of biological assets and challenges in laboratory services [1][2]. Group 1: Revenue and Profit Projections - The company anticipates revenue for 2025 to be approximately RMB 1.573 billion to RMB 1.738 billion, representing a decrease of about RMB 280 million to RMB 446 million compared to the previous year, which is a year-on-year decline of approximately 13.9% to 22.1% [1]. - Net profit attributable to shareholders is expected to be around RMB 233 million to RMB 349 million for 2025, an increase of approximately RMB 159 million to RMB 275 million compared to the previous year, reflecting a year-on-year increase of about 214.0% to 371.0% [1]. - The net profit excluding non-recurring gains and losses is projected to be approximately RMB 246 million to RMB 370 million, which is an increase of about RMB 223 million to RMB 346 million year-on-year, indicating a substantial increase of approximately 945.2% to 1,467.7% [1]. Group 2: Contributions and Challenges - The positive change in the fair value of biological assets is expected to contribute approximately RMB 452 million to RMB 500 million to net profit [1]. - The laboratory services and other business segments are projected to incur a net loss of approximately RMB 2.06 billion to RMB 1.3 billion, indicating challenges in this area [1]. - The increase in the fair value of biological assets is driven by rising market prices and natural growth, positively impacting the company's performance [2]. - Despite stable operations in the laboratory, revenue and gross margin from contractual obligations have decreased year-on-year due to intense prior industry competition, leading to a decline in profit contribution from laboratory services [2].